NASDAQ$ITOS

iTeos Therapeutics Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

Previous: $53.9K-100.0%
EPS (adj)

-$0.85

Previous: $0.54-257.4%
R&D Expenses

$27.9M

No prior period
G&A Expenses

$12.4M

No prior period
Capital Expenditures

-$1.41M

Previous: $117K-1306.8%
Free Cash Flow

-$15.2M

Previous: -$27.3M+44.4%
Net Income

-$30.6M

Previous: $20.5M-249.4%
Operating Income

-$40.1M

Previous: $17.4M-330.9%
Gross Profit

-$233K

Previous: $53.7M-100.4%
Cash & Equivalents

$532M

Previous: $285M+86.8%
Total Assets

$668M

Previous: $755M-11.6%
R&D Expense

$27.8M

No prior period
Stock-Based Comp

$7.19M

Previous: $5.89M+22.2%

Revenue & EPS history

iTeos Therapeutics · Revenue · Quarterly

$0

Q4 2023-100%vs Q4 2022
Beat estimate in 3 of 9 quarters(33%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.8%

Avg return

Earnings day

+7.3%

Avg return

5 days after

+11.8%

Avg return

30 days after

38%

8 / 21 earnings

Positive

+39.6%

Q1 2024

Best reaction

-11.1%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025+0.2%+0.0%
Q1 2025-0.4%+13.3%+52.2%
Q4 2024-3.7%-6.4%-11.4%
Q3 2024-5.9%-12.4%-15.6%
Q2 2024-3.4%+1.4%-3.1%
Q1 2024+39.6%+47.5%+36.9%
Q4 2023+5.1%+8.0%+12.0%
Q3 2023-3.1%
Q2 2023-2.6%
Q1 2023-0.8%
Q4 2022-7.7%
Q3 2022+16.2%
Q2 2022-9.4%
Q1 2022+3.2%
Q4 2021-3.6%
Q3 2021+1.4%
Q2 2021-1.5%
Q1 2021+8.5%
Q4 2020-11.1%
Q3 2020-4.2%
Q2 2020+0.0%
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro